

Attorney Docket No. 4660.240-US
Hansen et al.
Serial No. 10/067,895 Filed February 5, 2002
Via Fax No.: 703-872-9306

AMENDMENT

In the claims:


This Claim Listing will replace all prior versions and listings of claims in the application.

CLAIM LISTING

1. Cancelled
2. Cancelled
3. Cancelled
4. Cancelled
5. Cancelled
6. Cancelled
7. Cancelled
8. Cancelled
9. Cancelled
10. Cancelled
11. Cancelled
12. Cancelled
13. Cancelled
14. Cancelled
15. Cancelled
16. Cancelled
17. Cancelled
18. Cancelled
19. Cancelled
20. Cancelled
21. Cancelled
22. Cancelled
23. Cancelled

24. (Currently amended) A compound of Formula I

Attorney Docket No. 4660.240-US
Hansen et al.
Serial No. 10/067.895 Filed February 5, 2002
Via Fax No.: 703-872-9306




wherein


R^1 and R^2 are independently hydrogen, or C_{1-6} -alkyl;

a and b are independently 1 or 2;


G is



J is




or




Attorney Docket No. 4660.240-US
 Hansen et al.
 Serial No. 10/067,895 Filed February 5, 2002
 Via Fax No.: 703-872-9306

wherein R^{27} , R^{28} , R^{32} , R^{33} , R^{34} , R^{35} and R^{36} independently are hydrogen;

D is



or




wherein R^3 , R^4 , R^5 and R^6 are independently hydrogen or C_{1-6} alkyl,
 n , m , and q are independently 0, 1, 2, or 3;

when E is



wherein R^{12} is hydrogen and R^{13} is C_{1-6} -alkyl

or



wherein

X is $-\text{O}-$,

Z is $-\text{N}=$,

Attorney Docket No. 4660.240-US
Hansen et al.
Serial No. 10/067,895 Filed February 5, 2002
Via Fax No.: 703-872-9306

V is $-C(R^{16})=$

Y is $-N=$,

R^{16} is $-(CH_2)_wR^{19}$;

~~R^{12} , R^{13} and R^{19} are independently hydrogen or C_{1-6} alkyl
and w is independently 0, 1, 2 or 3;~~

wherein R^{19} is C_{1-6} -alkyl and w is independently 0, 1, 2 or 3,

or a pharmaceutically acceptable salt thereof.

25. (Previously presented) The compound according to claim 24, wherein D is piperidin-4-ylidenyl or 2-methylpiperidin-4-yl.



26. (Previously presented) The compound according to claim 24, wherein E is methylcarbonyl or 3-methyl-1,2,4-oxadiazol-5-yl.

27. (Previously presented) The compound according to claim 24, wherein R^1 and R^2 independently are hydrogen, methyl or ethyl.

28. (Previously presented) The compound according to claim 24, wherein a and b independently are 1.


29. (Currently amended) The compound according to claim 24, wherein said compound is

Attorney Docket No. 4660.240-US
Hansen et al.
Serial No. 10/067,895 Filed February 5, 2002
Via Fax No.: 703-872-9306



or

Attorney Docket No. 4660.240-US
Hansen et al.
Serial No. 10/067,895 Filed February 5, 2002
Via Fax No.: 703-872-9306



30. (Currently amended) A method of increasing rate and extent of growth, improving milk and/or wool production and/or treating ailments in an animal resulting from a deficiency of growth hormone, the method comprising administering to said animal in need thereof an effective amount of the compound according to claim 24 25.

31. (Currently amended) A composition comprising a compound according to claim 24 25 together with a pharmaceutically acceptable carrier or diluent.

32. (Previously presented) The composition according to claim 31 in unit dosage form, comprising from about 10 to about 200 mg of said compound.

33. (Previously presented) The composition according to claim 31 for oral, nasal, transdermal, pulmonary, or parenteral administration.

Attorney Docket No. 4660.240-US
Hansen et al.
Serial No. 10/067,895 Filed February 5, 2002
Via Fax No.: 703-872-9306

34.(Currently amended) A method of stimulating the release of growth hormone from the pituitary, the method comprising administering to a subject in need thereof an effective amount of the compound according to claim 24 ~~25~~.

35. (Previously presented) The method according to claim 34, wherein the effective amount of said compound is in the range of from about 0.0001 to about 100 mg/kg body weight per day.

36. (Previously presented) The method according to claim 34, wherein said administration is carried out by the oral, nasal, transdermal, pulmonary, or parenteral route.

37. (Previously presented) The method according to claim 34, wherein the effective amount of said compound is in the range of from about 0.001 to about 50 mg/kg body weight per day.